Elevation Oncology Inc (NASDAQ:ELEV)’s traded shares stood at 0.48 million during the last session, with the company’s beta value hitting 1.27. At the close of trading, the stock’s price was $0.54, to imply an increase of 3.40% or $0.02 in intraday trading. The ELEV share’s 52-week high remains $5.83, putting it -979.63% down since that peak but still an impressive 33.33% since price per share fell to its 52-week low of $0.36. The company has a valuation of $31.82M, with an average of 0.92 million shares in intraday trading volume over the past 10 days and average of 1.24 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Elevation Oncology Inc (ELEV), translating to a mean rating of 1.00. Of 5 analyst(s) looking at the stock, 0 analyst(s) give ELEV a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 5 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.2.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Elevation Oncology Inc (NASDAQ:ELEV) trade information
After registering a 3.40% upside in the last session, Elevation Oncology Inc (ELEV) has traded red over the past five days. The 5-day price performance for the stock is -8.75%, and -17.17% over 30 days. With these gigs, the year-to-date price performance is 0.26%. Short interest in Elevation Oncology Inc (NASDAQ:ELEV) saw shorts transact 6.26 million shares and set a 8.94 days time to cover.
The extremes give us $8 and $10 for target low and target high price respectively. As such, ELEV has been trading -1751.85% off suggested target high and -1381.48% from its likely low.
Elevation Oncology Inc (ELEV) estimates and forecasts
Looking at statistics comparing Elevation Oncology Inc share performance against respective industry, we note that the company has outperformed competitors. Elevation Oncology Inc (ELEV) shares are -89.03% down over the last 6 months, with its year-to-date growth rate higher than industry average at 38.81% against 17.60%. Revenue is forecast to grow 20.00% this quarter before falling -10.50% for the next one.
ELEV Dividends
Elevation Oncology Inc has its next earnings report out on 2024-Aug-06. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Elevation Oncology Inc (NASDAQ:ELEV)’s Major holders
Elevation Oncology Inc insiders hold 0.24% of total outstanding shares, with institutional holders owning 104.66% of the shares at 104.91% float percentage. In total, 104.66% institutions holds shares in the company, led by LOGOS GLOBAL MANAGEMENT LP. As of 2024-06-30, the company held over 3.85 million shares (or 6.5234% of shares), all amounting to roughly $10.39 million.
The next major institution holding the largest number of shares is FARALLON CAPITAL MANAGEMENT LLC with 3.6 million shares, or about 6.0971% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $9.72 million.
